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Abstract
Background: We describe molecular diagnosis in a complex consanguineous family: four offspring presented with
combinations of three distinctive phenotypes; non-syndromic hearing loss (NSHL), an unusual skeletal phenotype
comprising multiple fractures, cranial abnormalities and diaphyseal expansion, and significant developmental delay
with microcephaly. We performed Chromosomal Microarray Analysis on the offspring with either the skeletal or
developmental delay phenotypes, and linkage analysis and whole exome sequencing (WES) on all four children,
parents and maternal aunt.
Results: Chromosomal microarray and FISH analysis identified a de novo unbalanced translocation as a cause of
the microcephaly and severe developmental delay. WES identified a NSHL-causing splice variant in an autosomal
recessive deafness gene PDZD7 which resided in a linkage region and affected three of the children. In the two
children diagnosed with an unusual skeletal phenotype, WES eventually disclosed a heterozygous COL1A1 variant
which affects C-propetide cleavage site of COL1. The variant was inherited from an apparently unaffected mosaic
father in an autosomal dominant fashion. After the discovery of the COL1A1 variant, the skeletal phenotype was
diagnosed as a high bone mass form of osteogenesis imperfecta.
Conclusions: Next generation sequencing offers an unbiased approach to molecular genetic diagnosis in highly
heterogeneous and poorly characterised disorders and enables early diagnosis as well as detection of mosaicism.
Keywords: Next generation sequencing, Autosomal recessive non-syndromic hearing loss, PDZD7, Osteogenesis
imperfecta, Mosaicism, COL1A1 C-propeptide cleavage site
Background
Molecular genetic diagnosis is currently undergoing a
considerable transformation with the implementation of
next generation sequencing (NGS). The NGS tech-
niques, currently still imperfect, are becoming more ac-
curate as well as affordable, and innovative approaches
are being developed to address NGS limitations such as
detection of copy number variants (CNV) and structural
rearrangements [1]. With NGS generating whole exome
(WES) and whole genome sequences (WGS), data
management, variant interpretation and genetic counsel-
ling is often challenging.
Non-syndromic sensorineural hearing loss (NSHL) is
characterised by a high degree of genetic heterogeneity
which makes genetic diagnosis exceedingly difficult
using traditional Sanger sequencing techniques. At
present, 64 genes are implicated in the autosomal reces-
sive form, 35 in autosomal dominant and 4 in the X-
linked form [2]. The majority of NSHL causing variants
are rare and unique for individual families, with a few
notable exceptions.
Bone fragility with fractures in infancy or early child-
hood has been reported in over 100 genetic disorders
from skeletal dysplasias and inborn errors of metabolism
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to congenital insensitivity to pain [3]. The most common
genetic form of bone fragility is osteogenesis imperfecta
(OI). If relying solely on clinical evaluation, the diagnosis
of OI, which is phenotypically and genetically heteroge-
neous, might sometimes be missed either due to mild/
underdeveloped phenotype at the age of evaluation or
atypical presentation [3]. Molecular genetic diagnosis is
therefore instrumental for early and accurate clinical
diagnosis. COL1A1 and COL1A2 genes, which are re-
sponsible for more than 90% of all OI cases, are large
with over 50 exons, making genetic sequencing for OI
diagnosis time consuming and expensive. While bio-
chemical studies, connective tissue and skeletal dysplasia
panels are only helpful in some cases, whole exome and
genome sequencing enable efficient, unbiased screening
of all known genes involved in bone fragility as well as
having the potential for novel gene discovery.
Here we report on a consanguineous family segregat-
ing sensorineural hearing loss, an unusual skeletal
phenotype and microcephaly with significant develop-
mental delay. We describe detailed molecular investiga-
tion involving Chromosomal Microarray (CMA), linkage
analysis and whole exome sequencing (WES), which led
to molecular genetic diagnosis of all three phenotypes.
Methods
Patients
The family is a consanguineous family of Pakistani ori-
gin; parents are 1st cousins and the mother’s parents
were also 1st cousins.
The father (I-1) is healthy, the mother (I-2) and
mother’s sister (I-3) have non-syndromic hearing loss
(NSHL). The first child (II-1) has NSHL and an unusual
skeletal phenotype, the 2nd child (II-2) has NSHL only,
the 3rd child (II-3) was born with microcephaly, deep
set eyes, global developmental delay in addition to
NSHL and the 4th child (II-4) shares the skeletal pheno-
type of sibling II-1 only (Fig. 1). The 1st, 2nd and 3rd
children (II-1, II-2, II-3) failed the newborn hearing
screen; the 4th child (II-4) passed the newborn hearing
screen.
Non-syndromic hearing loss (NSHL) phenotype
The mother (I-2), mother’s sister (I-3), first and second
child (II-1 and II-2) have moderate congenital sensori-
neural hearing loss. The third child (II-3) was born with
severe deafness. The fourth child (II-4) passed the new-
born screen as well as subsequent visual enforcement
audiometry at 1 year. He has normal language develop-
ment. The father has normal hearing. The mother also
has four hearing impaired siblings and four siblings with
normal hearing (Fig. 1). Hearing loss is non-progressive
and stable. None of these adults have complained of any
visual symptoms and one hearing impaired sibling has
been tested and found to have a normal electroretino-
gram (ERG).
Skeletal phenotype
1st child (II-1): radiographic assessments were made be-
tween ages of 23 months and 8 years, including two
skeletal surveys. The 1st child sustained fractures of the
left 4th and 5th proximal phalanges aged 23 months,
and of the left tibial and fibular diaphyses 1 month later
when she fell from her cot. There was no evidence of
blue sclerae. At the age of 4 years teeth showed dental
caries but no dentinogenesis imperfecta. She was also
Fig. 1 Family pedigree showing the genotypes segregating with the non-syndromic hearing loss, skeletal phenotype and developmental delay
with microcephaly
Le Quesne Stabej et al. Orphanet Journal of Rare Diseases  (2017) 12:24 Page 2 of 8
noted at age 6 years to have pars defects of the 5th lum-
bar vertebra with grade 1 spondylolisthesis. On skeletal
survey (Fig. 2a-d), the following radiological features
were observed: abnormal Wormian bones with persist-
ent anterior fontanelle at aged 2; shortening of the ulnae
with varus bowing of the radii, and radial head disloca-
tion from age 5; diaphyseal expansion (undermodelling)
of the tubular bones, particularly the ribs and short
tubular bones; abnormal coarse trabecular pattern in
short tubular bones; no radiological evidence of osteope-
nia or vertebral body fractures. Bone density assessment
by lumbar spine DEXA at aged 5 was normal (BMAD z-
score 0.45), but was significantly increased at ages 6 and
7 (BMAD z z-scores 2.39 and 2.63 respectively).
4th child (II-4): radiographic assessments were made
between the ages of 10 days and 19 months, including a
skeletal survey (Fig. 2e-g). He sustained fractures of the
right humerus perinatally and left femur age 6 months.
At age 11 months, multiple Wormian bones and short-
ening of the ulnae were apparent. Diaphyseal expansion
of the ribs and short tubular bones, with abnormal tra-
beculation, were not apparent at birth, but these features
were starting to appear aged 19 months. DEXA z-scores
are not available before the age of 5.
The key shared features in this sibling pair are: bony
fragility in first 2 years of life; abnormal Wormian bone
pattern with late fontanelle closure; mesomelic upper
limb shortening with short ulna and bowed radius;
undermodelling of tubular bones, particularly ribs and
hands, with abnormal trabeculation in the hands; no
osteopenia.
Informed consent for the study was obtained from all
participants or their parents and genetic studies were
approved by the Bloomsbury National Research Ethics
Service (Reference number 08/H0713/82). Genomic
DNA of the proband and family members was extracted
from peripheral blood by standard methods.
Developmental delay and microcephaly phenotype
The third child was born at 38 weeks with a birthweight
of 2.807 kg following a normal pregnancy and delivery
by forceps. She failed the newborn hearing screen and
was subsequently fitted with hearing aids. During the
first year of life she was diagnosed with global develop-
mental delay and all developmental milestones were
delayed. There were initial feeding and swallowing diffi-
culties which resolved after a few months. She sat inde-
pendently at 1 year. At the age of 16 months her head
Fig. 2 Child II-1. a Lateral skull radiograph aged 2 years (a frontal view was not performed at this time). The anterior fontanel is patent. There are
multiple Wormian bones around the lambda. b Child II-1. Radiograph of left tibia and fibula aged 2 years. There are transverse fractures of the
tibia and fibula. The tibia is undermodelled. Bone density appears increased. c-d Child II-1. Radiographs of the right and left upper limbs aged
2 years. There is pronounced ulnar shortening particularly distally, with varus bowing of the forearm bones. e-g Child II-4. Lateral skull radiograph
demonstrates multiple Wormian bones and radiographs of the forearms aged 11 months ulnar shortening
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was on the 0.4th centile, weight was just above the 9th
centile and height was just below the 0.4th centile. She
learned to stand at 20 months, which was when she was
last seen. She was observed to have deep-set eyes, a
prominent nasal bridge, microbrachycephaly and large
ears. She has a structurally normal heart, hypermetropia
and a normal electroretinogram. Biochemical investiga-
tions including plasma amino acids, vacuolated lympho-
cytes, isoelectric focussing of transferrins, very long
chain fatty acids, lactate, white cell enzymes, calcium,
phosphate and parathyroid hormone levels as well as
urea and electrolytes and liver function tests were all
normal.
Microarrays and linkage analysis
The parents and offspring with the skeletal (1st and 4th
child) or developmental delay (3rd child) phenotypes
were subjected to routine Chromosomal Microarray
Analysis (CMA) either by Comparative Genomic
Hybridisation (CGH) using Roche Nimblegen 135 K
microarray or by cytogenomic SNP microarray using
Affymetrix Cytoscan 750 K as per manufacturer’s
instructions. Multipoint parametric linkage studies of all
seven members of the family (Fig. 1) was performed
using the HumanCytoSNP-12v2-1_H Beadarray (Illu-
mina, Inc, San Diego, CA) as per the manufacturer’s
instructions as published previously [4]. A recessive
transmission model with complete penetrance and a dis-
ease allele frequency of 0.0001 was used for linkage ana-
lysis for deafness and for skeletal dysplasia initially.
Whole exome and Sanger sequencing
Whole exome capture was performed with Agilent Sure-
Select version 4 (Santa Clara, CA), according to manu-
facturer’s protocol on all seven family members.
Enriched libraries were sequenced on the Illumina (San
Diego, CA) HiSeq2000. Sequencing reads passing quality
filters were aligned to the reference genome build
GRGh37/hg19 using Burrows-Wheeler Aligner (BWA)
algorithm and for variant calling we applied GATK [5]
base quality score recalibration, indel realignment, dupli-
cate removal, and performed SNP and INDEL discovery
and genotyping using standard hard filtering parameters
or variant quality score [6].
The variant annotation and interpretation analyses
were generated through the use of Ingenuity® Variant
Analysis™ software version 3.1.20140902 from Ingenuity
Systems. For the recessive model, homozygous/com-
pound heterozygous variants shared between affected in-
dividuals were retained; for a dominant model, we
retained heterozygous variants in common between
affected individuals. Intronic and exonic synonymous
variants were filtered out; exonic and splice variants (up
to seven base pairs into intron or predicted pathogenic
on MaxEntScan) with a public databases (ExAC, 1000
Genomes and ESP Exomes) frequency <0.1% (NSHL
phenotype) and <0.01% (skeletal phenotype) were
retained. Separate filtering steps were applied for NSHL
and skeletal phenotypes.
Disease causing variants (PDZD7 and COL1A1) were
validated by Sanger sequencing. Primers were developed
using Primer3 software (see Additional file 1 for primer
sequences).
RNA isolation and PDZD7 RT-PCR
Blood samples from parents and all four children were
collected into Paxgene™ RNA tubes and RNA from
whole blood was extracted according to manufacturer’s
protocol using the PAXgene Blood RNA System (PreAn-
alytiX, Hombrechtikon, CH). Synthesis of cDNA was
carried out using Omniscript™ RT (Qiagen, Santa Clarita,
CA) system according to supplier’s protocol. PCR primer
sequences used to amplify PDZD7 exons 1–15 are listed
in Additional file 2.
Results
Chromosomal Microarray Analysis (CMA)
Copy number variants (CNV) identified by CMA were
analysed with respect to gene content, presence on pub-
lic databases (DECIPHER, DGV) and whether they seg-
regated with one of the phenotypes. CMA identified
monosomy 8p23 with a loss of material of approximately
10,6 Mb between 8:176,569 and 10,781,689 and partial
trisomy 18 with a gain of approximately 7.9 Mb between
co-ordinates 18:141,489-8,022,950, suggesting a de novo
unbalanced translocation between chromosomes 8 and
18 as the cause of severe developmental delay with
microcephaly in the 3rd child (II-3). More than 100
genes are either deleted or duplicated by the unbalanced
translocation and are likely to contribute to the pheno-
type of the patient. These include three DDG2P genes on
chromosome 18 (TGIF1, LAMA1, SMCHD1) and three
on chromosome 8 (CLN8, MCPH1, FBOX25) [7, 8]. Dele-
tion of this region of chromosome 8 has been reported in
association with developmental delay and microcephaly.
Duplication of a similar region of chromosome 18 has
been described associated with developmental delay and
behavioural problems. The translocation was not observed
in any other family member and was thought to be
responsible for the significant developmental delay and
microcephaly phenotypes, but not the NSHL. No further
CNVs were identified that could explain any of the clinical
phenotypes.
Linkage analysis
Multipoint parametric linkage analysis showed six
regions with significant linkage (logarithm of odds
scores, LOD > 3.0) to the NSHL phenotype using a
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recessive model; i.e. on chromosomes 3, 4, 7, 10 (two
regions) and 13 (Additional files 3 and 4).
Linkage analysis though failed to reveal any regions
significantly linked to the skeletal phenotype (Additional
file 5) using a recessive model. Despite a lack of signifi-
cant LOD scores in the skeletal phenotype analysis, we
looked for homozygous and compound heterozygous
variants in the linkage intervals with LOD scores greater
than 2 (i.e. between 2.0172 and 2.0556 on chromosomes
5, 9, 14 and 16) shared between the two sibs affected
with skeletal phenotype (Additional file 5). There were
no rare variants (less frequent than 1% in public data-
bases) in the exonic or splice (up to +/−7 into an intron)
regions shared between the two sibs and not shared by
skeletal phenotype unaffected sibs. We also manually
inspected the BAM files for potential larger deletions in
these regions and failed to find any.
Whole Exome Sequence (WES) analysis
Whole exome sequence with mean 70× coverage was
generated for the parents, all four children and the
mother’s sister. Separate analyses were performed for the
NSHL and skeletal phenotypes.
For the NSHL phenotype, only the PDZD7 NM_0011
95263.1:c.226 + 2_226 + 5del (hg19.chr10:g.102789746_
102789749del) variant passed the genetic filter (Fig. 1). It
also resided in the linkage region on chromosome 10
with a significant LOD score of 3.6 (Additional files 3
and 4). The PDZD7 c.226 + 2_226 + 5del variant is a
homozygous deletion of four base pairs at the exon 2 -
intron 2 junction. The deletion affects the invariant
splice site and is therefore predicted to affect splicing.
The PDZD7 c.226 + 2_226 + 5del was not found in any
public databases (ExAC, ESP Exomes, 1000 Genomes
and gnomAD) [9].
WES analysis to find the variant causing the skeletal
phenotype proved challenging; in line with the absence
of linkage regions, we found no potential recessive dis-
ease causing variants shared between the two affected
sibs with the skeletal phenotype. This led us to consider
an autosomal dominant scenario, with the disease-
causing variant inherited from a parent who was either a
gonosomal or gonadal mosaic. There were no de novo
variants shared between the two affected sibs which
were absent in parents or other unaffected sibs; pure
gonadal mosaicism was therefore excluded. In order to
investigate gonosomal mosaicism, we looked for variants
shared between affected sibs, but not unaffected sibs,
and possibly present in either parent. There were nine
rare (<0.01% in public databases) good quality heterozy-
gous exonic/splice variants shared between the two sibs
affected with the skeletal phenotype and not called in
unaffected sibs, but present in either one of the parents.
We assessed the proportions of reads carrying the
alternate allele (allele fraction – AF) in all nine variants
in the parents. While the average allele fraction in all
heterozygous variants was 47%, the COL1A1 NM_000
088.3:c.3652G > A (chr17.hg19:48264163C > T) heterozy-
gous variant had an AF of only 21% in the father; i.e. of
the 377 aligned paternal reads, 78 carried the alternate
allele “T” while 299 carried the reference allele “C”. By
contrast, children affected with the skeletal phenotype
II-1 and II-4 carried the alternate variant in 49% and
52% of reads, respectively (Figs. 1 and 3). The paternal
mosaicism as well as the presence/absence of the
COL1A1 variant in the other family members has been
confirmed by Sanger sequencing. COL1A1 c.3652G > A
(p.Ala1218Thr) is not present in any public database
(ExAC, ESP Exomes, 1000 Genomes or gnomAD [9]), is
conserved in 100 vertebrates and is predicted to be dele-
terious and disease causing according to SIFT and Muta-
tionTaster, respectively.
PDZD7 cDNA
The 4-nucleotide deletion in PDZD7 (c.226 + 2_226 +
5delTAGG) is predicted to affect splicing as it abolishes
the invariant GT splice site at the exon 2 - intron 2 junc-
tion. On the cDNA level, we confirmed the presence of
a PDZD7 product spanning exons 1–2 in the family
members affected with NSHL as well as unaffected
members, demonstrating that this part of the transcript
was expressed at detectable levels in lymphocyte RNA.
However, we were not able to amplify PDZD7 exons 3–17
in individuals affected with NSHL. In the NSHL un-
affected heterozygous father, and in normal controls we
were able to obtain a product spanning exons 2–6, 5–8
and 13–15, but Sanger sequencing of these products re-
vealed that in the father, only the allele not carrying the
c.226 + 2_226 + 5deletion was amplified (ie. only wild-type
was expressed). The distinction between the two alleles
was possible due to the presence of SNPs rs148746572
residing in PDZD7 exon 6 and rs547610251 in exon 15; in
the whole exome genomic sequence the father is heterozy-
gous for both SNPs, but in the cDNA sequence he is
hemizygous (Additional files 6 and 7).
Discussion
Here we demonstrate the efficiency of WES in solving
the underlying molecular diagnoses in a family with
complex phenotypes. While conventional Chromosomal
Microarray was quick to indicate an unbalanced trans-
location, with monosomy of 8p23 and partial trisomy of
chromosome 18 as the cause of severe developmental
delay and microcephaly in the 3rd child, the causes of
the NSHL and uncharacterised skeletal phenotypes in
the remaining siblings were more challenging. A first-
generation inherited hearing loss panel with 55 deafness
genes failed to establish genetic diagnosis of NSHL since
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PDZD7 had not been associated with NSHL and due to
the unusual presentation the skeletal phenotype eluded a
definite clinical diagnosis. By the time the 4th child was
born, all available family members underwent linkage
analysis and whole exome sequencing. As expected
(based on strong history of NSHL on the mother’s side,
consanguinity as well as multiple affected family mem-
bers), the genetic cause of NSHL was a variant inherited
in an autosomal recessive manner - a homozygous
PDZD7c.226 + 2_226 + 5del at the exon 2 – intron 2
junction which involves the invariant GT splice site.
PDZD7 gene was initially described as a modifier of the
retinal phenotype in Usher syndrome; more recently
however, it has been shown to cause autosomal recessive
NSHL [10–12].
The COL1A1c.3652A > G (p.Ala1218Thr) variant,
which was inherited in an autosomal dominant manner
from a mosaic father, has previously been described in a
mother and son with ‘gnathodiaphyseal dysplasia’ and in
two siblings diagnosed as ‘osteogenesis imperfecta with
increased bone mineral density’ (BMD) [13, 14]. The
two sibs described in our report had no jaw lesions or
late tooth eruption as described in the gnathodiaphyseal
dysplasia case. The common denominators with the
gnathodiaphyseal case were multiple fractures, elevated
BMD and late fontanelle closure. Multiple fractures and
elevated BMD were also the characteristics of OI with
increased BMD described by Cundy et al. But unlike the
pediatric patients in our study, the affected sibs
described there also had a significant conductive hearing
loss and osteosclerosis; this might be due to age-related
penetrance [14].
Type I collagen is a triple-helical molecule composed
of two alpha-1 chains and one alpha-2 chain, encoded
by COL1A1 and COL1A2. After the assembly of the
chains into a triple helix, the N- and C-propeptides are
cleaved by proteinases. Substitutions in the COL1A1
and COL1A2 cleavage sites block the removal of the C-
propeptide tails from type I procollagen and result in
incorporation of a molecule with retained C-propeptide.
The variant reported here is one of the four conserved
C-propeptide cleavage site residues (together with
Asp1219 in COL1A1, Ala1119 and Asp1120 in
COL1A2) that affects the alanine at position 1218 and is
expected to abolish the C-propeptide cleavage site. Inter-
estingly, patients with COL1 cleavage site variants had
different clinical presentations, but increased bone
mineralisation with multiple fractures was described in
most cases (see Table 2 in McInerney-Leo et al. 2015)
[13–15]. After the discovery of COL1A1 c.3652A > G
mosaicism in the father, the asymptomatic father was
examined radiographically (age 28 years). The hands
showed subtle diaphyseal expansion of the metacarpals
only but no signs of old fractures. Skull sutures were in-
distinct, but there was no clear abnormal Wormian bone
pattern. An orthopantomogram did not show sclerotic
jaw lesions. The ulnae showed minor negative minus
variance, within normal limits. Lumbar spine DEXA
Fig. 3 BAM and Sanger sequence traces showing COL1A1 c.3652G > A variant: heterozygous in the two affected children (II-1, II-4) with skeletal
phenotype and mosaic in the father (I-1)
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revealed significantly elevated bone mass with age-
matched z-score of 3.6 indicating a sub-clinical
phenotype.
Conclusions
In conclusion, due to clinical and genetic heterogeneity
of skeletal and hearing loss disorders as well as a clinical
picture in pediatric patients which is not always fully
manifest at presentation or which is atypical, early diag-
nosis is difficult. Whole exome sequence analysis was
instrumental in establishing the molecular genetic diag-
nosis in this family and is sensitive enough to detect mo-
saicism, if suspected. Although NGS platforms are still
evolving and imperfect, they are invaluable at this
present time as they offer simultaneous unbiased evalu-
ation of all exonic/genomic variants and are rapidly
making their way into clinical genetic diagnostics.
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